{"meta":{"query_hash":"f8fc74a05c8b","filters":{"venue":"Reviews on Clinical Pharmacology and Drug Therapy"},"cohort_total":1,"direct_labels_cover":0,"predictions_cover":1,"exported":1,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/f8fc74a05c8b","api":"https://metacan.xera.ac/api/v1/cohort?venue=Reviews+on+Clinical+Pharmacology+and+Drug+Therapy"},"results":[{"id":"W3165297872","doi":"10.17816/rcf19137-46","title":"Hypolipidemic drugs inhibiting the proprotein convertase of subtilisin/kexin type 9 (PCSK9): monoclonal antibodies, antisense oligonucleotides, small interfering ribonucleic acids","year":2021,"lang":"en","type":"article","venue":"Reviews on Clinical Pharmacology and Drug Therapy","topic":"Lipoproteins and Cardiovascular Health","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"PCSK9; Proprotein convertase; Kexin; Alirocumab; LDL receptor; Evolocumab; Pharmacology; Chemistry; Subtilisin; Monoclonal antibody; Cholesterol; Lipoprotein; Biochemistry; Antibody; Biology; Enzyme; Immunology","score_opus":0.09023443268592535,"score_gpt":0.39690194238444304,"score_spread":0.3066675096985177,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3165297872","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.36931637,0.56887764,0.03263909,0.00305965,0.002293451,0.00048769312,0.0012974748,0.0010129724,0.021015726],"genre_scores_gemma":[0.7211393,0.24082272,0.014671082,0.0013563961,0.0006820219,0.0004942225,0.0012838873,0.00004996481,0.01950044],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9999237,0.000010469214,0.0000095716805,0.000019626745,0.00002449815,0.0000121532585],"domain_scores_gemma":[0.9999707,0.0000059378053,0.0000090639205,0.0000022735585,0.0000069454677,0.0000051812985],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016022116,0.00036680003,0.0003250526,0.00050114776,0.00013272984,0.0002685366,0.00015469654,0.00028509495,0.0014674279],"category_scores_gemma":[0.000117713826,0.000100462115,0.000243801,0.00029260607,0.00019916128,0.00020479513,0.00019775421,0.0007790048,0.00070701574],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001346806,0.00044847353,0.0005496209,0.001263611,0.000064825275,0.00024872937,0.000039160226,0.0002632002,0.6727438,0.0019437915,0.003545908,0.31754208],"study_design_scores_gemma":[0.0009477822,0.0052520484,0.007069956,0.00016518781,0.00028854635,0.0027314434,0.000039268973,0.001233682,0.7436743,0.0009811899,0.23757283,0.00004365202],"about_ca_topic_score_codex":0.00038224438,"about_ca_topic_score_gemma":0.00057033007,"teacher_disagreement_score":0.0014674279,"about_ca_system_score_codex":0.00023348132,"about_ca_system_score_gemma":0.00014819088,"threshold_uncertainty_score":0.0049090385},"labels":[],"label_agreement":null}]}